The purpose of this study is to evaluate the safety and tolerability of N6022 in healthy subjects.

This is a single dose escalation, first-time-in-human study with three ascending cohorts. Eligible subjects will receive a single dose of investigational medicinal product or placebo on Day 1 and will be followed for safety, PK, and PD for 72 hours post dose. Follow-up visits on Day 4 and Day 7 for the end-of-study safety. Participation of an individual subject may last up to 36 days from the time of screening until the end-of-study follow-up visit. Each cohort will enroll a sentinel pair (1:1 randomized to active: placebo). These subjects will be followed for 48 hours postdose and safety data reviewed before the remaining subjects in the cohort receive IMP. A Safety Monitoring Committee will review the seven-day safety data in each cohort before proceeding to the next ascending dose cohort, according to the stopping rules outlined in the protocol.

Inclusion:

• Subject is healthy

Exclusion:

• Subject is a current alcohol abuser and/or has a history of illicit drug abuse within six months of entry.
• Subject has donated blood (> 500 mL) or blood products within 56 days prior to Day -1

Any subject that received any active or placebo

6 months and 2 weeks